Merkel cell carcinoma is a rare neuroendocrine skin cancer that affects around 300 Australians each year.
This is an extremely aggressive cancer that can rapidly spread to other sites of the body. Unfortunately only 18% of patients with metastatic Merkel cell carcinoma are expected to survive for five years.
Recent data suggests that the combination of radiotherapy and immunotherapy is one of the most effective treatment options for treating metastatic Merkel cell carcinoma. As part of the Melanoma and Skin Cancer (MASC) trials, the GoTHAM trial aims to investigate the effectiveness of combining the immunotherapy drug Avelumab with either conventional radiotherapy or peptide receptor radionuclide therapy.
To be eligible for this trial, participants must be:
- Aged over 18
- Have histologically confirmed metastatic Merkel cell carcinoma
- Are treatment naïve in the metastatic setting
- Have an ECOG Performance Status of 0-2
- Have normal organ function
Recruiting sites are available around Australia, including:
- Peter MacCallum Cancer Centre (VIC)
- Royal North Shore Hospital (NSW)
- Royal Adelaide Hospital (SA)
- Royal Brisbane and Women’s Hospital (QLD)
- Princess Alexandra Hospital (QLD)
- Sir Charles Gairdner Hospital (WA)